Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Non Operating Income (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Non Operating Income for 15 consecutive years, with $28.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 38.35% year-over-year to $28.5 million, compared with a TTM value of $86.3 million through Dec 2025, up 202.13%, and an annual FY2025 reading of $86.3 million, up 202.13% over the prior year.
  • Non Operating Income was $28.5 million for Q4 2025 at Neurocrine Biosciences, down from $52.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $52.8 million in Q3 2025 and bottomed at -$64.8 million in Q1 2024.
  • Average Non Operating Income over 4 years is $6.1 million, with a median of $8.7 million recorded in 2023.
  • The sharpest move saw Non Operating Income crashed 694.5% in 2024, then surged 712.31% in 2025.
  • Year by year, Non Operating Income stood at -$14.0 million in 2021, then soared by 442.14% to $47.9 million in 2023, then plummeted by 56.99% to $20.6 million in 2024, then surged by 38.35% to $28.5 million in 2025.
  • Business Quant data shows Non Operating Income for NBIX at $28.5 million in Q4 2025, $52.8 million in Q3 2025, and $13.9 million in Q2 2025.